Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cardiovascular devices

This article was originally published in Start Up

Executive Summary

Two areas of heart disease in want of therapeutic solutions are attracting device innovation: atrial fibrillation and congestive heart failure. Successful developers will be rewarded by large markets with little in terms of current competition.

You may also be interested in...

AHA Wrap-Up: Studies Emphasize Improved Outcomes, Cost Effectiveness

Cardiovascular investigators are now asking new questions, including how can treatment be targeted to those most likely to benefit, and when does aggressive treatment become too much? At the 2006 American Heart Association (AHA) meeting, these questions were at the top of everyone's list, and several highly anticipated studies attempted to provide some answers.

Deal Statistics Quarterly, Q2 2005

In this issue, we present another installment of our quarterly review of dealmaking-for April-June 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.


Cardiovasc has a technology for growing functional endothelial cells in places where they normally do not grow. The company's two-part platform is built on a surface activation process that covalently bonds agents to materials, and a synthetic peptide, P-15, that attracts and anchors endothelial cells. The company's initial product will be a catheter-delivered stent, coated with the peptide, designed to encourage complete endothelialization and renew the interiors of aged and failing saphenous vein coronary bypass grafts.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts